US Patent Issued to EDITAS MEDICINE, JUNO THERAPEUTICS on Aug. 4 for "Methods, compositions and components for CRISPR-Cas9 editing of TGFBR2 in T cells for immunotherapy" (Washington, Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,489, issued on Aug. 4, was assigned to EDITAS MEDICINE INC. (Cambridge, Mass.) and JUNO THERAPEUTICS INC. (Seattle).

"Methods, compositions and components for CRISPR-Cas9 editing of TGFBR2 in T cells for immunotherapy" was invented by Stephen Michael Burleigh (Seattle), Melissa Chin (Cambridge, Mass.), Fred Harbinski (Cambridge, Mass.), Christopher Heath Nye (Seattle), Blythe D. Sather (Seattle), Queenie Vong (Seattle), Gordon Grant Welstead (Cambridge, Mass.) and Chris Wilson (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "CRISPR/CAS-related genome editing systems, compositions and methods for targeting the TGFBR2 locus, as well as ...